Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Enterprise ValueMarket Capitalization

Immuneering (IMRX) Return on Sales: 2021-2022

Historic Return on Sales for Immuneering (IMRX) over the last 2 years, with Dec 2022 value amounting to -160.06%.

  • Immuneering's Return on Sales fell 14385.00% to -160.06% in Q4 2022 from the same period last year, while for Dec 2022 it was -160.06%, marking a year-over-year decrease of 14385.00%. This contributed to the annual value of -159.37% for FY2022, which is 14325.00% down from last year.
  • According to the latest figures from Q4 2022, Immuneering's Return on Sales is -160.06%, which was down 67.94% from -95.31% recorded in Q3 2022.
  • Immuneering's Return on Sales' 5-year high stood at -7.63% during Q1 2021, with a 5-year trough of -160.06% in Q4 2022.
  • For the 2-year period, Immuneering's Return on Sales averaged around -46.49%, with its median value being -21.39% (2022).
  • Data for Immuneering's Return on Sales shows a maximum YoY crashed of 14,385bps (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows Immuneering's Return on Sales stood at -16.21% in 2021, then crashed by 14,385bps to -160.06% in 2022.
  • Its Return on Sales was -160.06% in Q4 2022, compared to -95.31% in Q3 2022 and -46.11% in Q2 2022.